AnaptysBio (ANAB) Expected to Release Quarterly Earnings on Tuesday

AnaptysBio (NASDAQ:ANAB) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect AnaptysBio to announce earnings of ($1.84) per share and revenue of $25.56 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $5.57. The business had revenue of $27.49 million during the quarter, compared to the consensus estimate of $14.06 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. During the same quarter last year, the firm earned ($1.30) earnings per share. On average, analysts expect AnaptysBio to post ($1.30) EPS for the current fiscal year and $2.42 EPS for the next fiscal year.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $48.77 on Tuesday. AnaptysBio has a 1 year low of $20.18 and a 1 year high of $72.36. The firm has a 50-day simple moving average of $52.70 and a two-hundred day simple moving average of $56.21. The company has a market cap of $1.46 billion, a P/E ratio of 9.08 and a beta of 0.76.

Analyst Upgrades and Downgrades

ANAB has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a research note on Tuesday, September 22nd. TD Cowen dropped their price objective on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a research report on Tuesday, August 25th. Finally, Wolfe Research reiterated an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a research note on Monday, August 31st. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $77.79.

Insider Transactions at AnaptysBio

In related news, Director Hollings Renton sold 5,000 shares of AnaptysBio stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total transaction of $249,350.00. Following the transaction, the director directly owned 10,995 shares of the company’s stock, valued at $548,320.65. This trade represents a 31.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by insiders.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.